Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2016-001031-13 | EudraCT Number |
Not provided
Not provided
Not provided
Business objectives have changed
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Open label, randomized, 4-period crossover study with single doses of BMS-986141 given to healthy female subjects of non-childbearing potential and healthy males.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Active Comparator | Single oral dose BMS-986141 Form A tablet under fasting conditions |
|
| B | Experimental | Single oral dose BMS-986141 Form B tablet (low-dose) under fasting conditions |
|
| C | Experimental | Single oral dose BMS-986141 Form B tablet (high-dose) under fasting conditions |
|
| D | Experimental | Single oral dose BMS-986141 Form B tablet (high-dose) under fed conditions |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-986141 Form A Tablet | Drug | tablet |
| |
| BMS-986141 Form B tablet (low dose) |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate the bioavailability between BMS-986141 Form B tablet compared to the Form A reference tablet | 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Further characterize safety and tolerability of BMS-986141 by assessing adverse events and other physical assessments throughout study conduct | 4 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
tablet |
|
| BMS-986141 Form B tablet (high dose) | Drug | tablet |
|